Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT01176344




Registration number
NCT01176344
Ethics application status
Date submitted
4/08/2010
Date registered
6/08/2010
Date last updated
9/09/2015

Titles & IDs
Public title
VItamin D Effect on Osteoarthritis Study
Scientific title
Does Vitamin D Supplementation Prevent Progression of Knee Osteoarthritis? A Randomised Controlled Trial
Secondary ID [1] 0 0
VIDEO605501
Universal Trial Number (UTN)
Trial acronym
VIDEO
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Osteoarthritis, Knee 0 0
Condition category
Condition code
Musculoskeletal 0 0 0 0
Osteoarthritis

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Vitamin D
Treatment: Drugs - Placebo

Experimental: Vitamin D supplementation - Participants in the intervention arm will receive 50,000 IU (1.25 mg) cholecalciferol capsules given once monthly

Placebo Comparator: Placebo - The control arm will receive identical inert placebo capsules given once monthly.


Treatment: Drugs: Vitamin D
50,000 IU (1.25 mg) cholecalciferol capsules once monthly for 2 years

Treatment: Drugs: Placebo
Inert placebo capsules once monthly for 2 years.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Loss of knee cartilage volume
Timepoint [1] 0 0
Over 2 years (Cartilage volume will be assessed at baseline and 2 years later)
Primary outcome [2] 0 0
Change in knee pain
Timepoint [2] 0 0
Over 2 years
Secondary outcome [1] 0 0
Progression of knee cartilage defects
Timepoint [1] 0 0
Over 2 years (Cartilahe defects will be measured at baseline and 2 years later)
Secondary outcome [2] 0 0
Change in bone marrow lesions
Timepoint [2] 0 0
Over 2 years
Secondary outcome [3] 0 0
Change in knee pain
Timepoint [3] 0 0
Over 2 years
Secondary outcome [4] 0 0
Change in physical function
Timepoint [4] 0 0
Over 2 years
Secondary outcome [5] 0 0
Change in joint effusion
Timepoint [5] 0 0
Over 2 years
Secondary outcome [6] 0 0
Central blood pressure
Timepoint [6] 0 0
one year
Secondary outcome [7] 0 0
Aortic stiffness
Timepoint [7] 0 0
one year

Eligibility
Key inclusion criteria
1. Age 50-79 years old;

2. Men and women with symptomatic knee osteoarthritis (OA) with a pain visual analogue
scale (VAS) of at least 20 mm in most days of the last month;

3. Have an American College of Rheumatology (ACR) functional class rating of I, II and
III;

4. Have relatively good health (0-2 according to the investigator's global assessment of
disease status on a 5-point Likert scale, range 0 [very well] to 4 [very poor]);

5. Have serum vitamin D level of >12.5 nmol/L and <60 nmol/L;

6. Are able to read, speak and understand English, capable of understanding the study
requirements and willing to co-operate with the study instructions;

7. Are able and willing to give informed consent;

8. Are willing and able to give blood samples;

9. Are willing and able to have knee MRIs performed
Minimum age
50 Years
Maximum age
79 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Have Grade 3 radiographic changes in their knee which is to be investigated;

2. Have severe knee pain (more than 80 mm on a 100-mm visual analogue scale,VAS) in most
days of the last month;

3. Have any contra-indications for having MRIs scans performed;

4. Have had significant trauma to the knees including arthroscopy or significant injury
to ligaments or menisci of the knee within 1 year preceding the screening visit;

5. Have ever had knee joint replacement;

6. Have anticipated need for knee or hip surgery in the next 2 years;

7. Have any stomach or intestinal condition possibly affecting oral drug absorption;

8. Have any clinically significant condition(s) such as (but not limited to) rheumatoid
arthritis, psoriatic arthritis, lupus, active cancer, cardiac or renal function
impairment or hypersensitivity to vitamin D that in the opinion of the investigator
may compromise their safety or compliance, interfere with evaluation or preclude
completion of the study.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/08/2010
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/12/2014
Sample size
Target
Accrual to date
Final
413
Recruitment in Australia
Recruitment state(s)
TAS,VIC
Recruitment hospital [1] 0 0
Menzies Research Institute, University of Tasmania - Hobart
Recruitment hospital [2] 0 0
Department of Epidemiology & Preventive Medicine, Monash University - Melbourne
Recruitment postcode(s) [1] 0 0
7000 - Hobart
Recruitment postcode(s) [2] 0 0
3004 - Melbourne

Funding & Sponsors
Primary sponsor type
Other
Name
Menzies Institute for Medical Research
Address
Country
Other collaborator category [1] 0 0
Other
Name [1] 0 0
Monash University
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
Observational evidence suggests that vitamin D deficiency may have a role in the causes of
osteoarthritis (OA) and there are biologically plausible mechanisms to explain this. There
is, however, no evidence which shows that intervening with vitamin D supplementation can slow
the progression of OA. This study is to determine if vitamin D supplementation can reduce
knee pain and slow knee cartilage loss in OA patients comparing with a placebo. Use of MRI
will provide sensitive measures of knee OA changes.
Trial website
https://clinicaltrials.gov/ct2/show/NCT01176344
Trial related presentations / publications
Ding C, Cicuttini F, Parameswaran V, Burgess J, Quinn S, Jones G. Serum levels of vitamin D, sunlight exposure, and knee cartilage loss in older adults: the Tasmanian older adult cohort study. Arthritis Rheum. 2009 May;60(5):1381-9. doi: 10.1002/art.24486.
Public notes

Contacts
Principal investigator
Name 0 0
Changhai Ding, MD
Address 0 0
Menzies Research Institute & Monash University
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT01176344